Our vaccine to treat dogs with chronic pain is the result of over a decade of research that began at the Neurodegeneration Laboratory of the Institut Pasteur de Montevideo and led to the creation of Xeptiva. Our scientific team has focused for years on thoroughly understanding the biological and physiological mechanisms underlying chronic inflammation and pain, with the goal of developing innovative therapeutic strategies to neutralize these processes. In 2021, our team of researchers decided to take a step further and create Xeptiva Therapeutics to develop therapies for pain in companion animals. This led to the first prototype of the vaccine, made from synthetically designed proteins that have the capacity of neutralizing the mechanisms that cause chronic inflammation and pain in animals. |
After years of studies confirming the safety and tolerance of this compound in laboratory animals and dogs with chronic pain, Xeptiva now has the first GMP’quality vaccine, meaning it meets a series of international manufacturing standards that ensure its safety.
The industrial production of this first GMP-quality vaccine would not have been possible without significant investment in economic and human resources. Biotech development requires long-term commitment. For over 10 years, we have allocated funds for basic research, acquisition of new technologies, and ongoing training for our team at all levels.
It is crucial to highlight the collaboration with academic institutions such as the Institut Pasteur de Montevideo and industrial partners like ATGEN and Merck Argentina, as they have been fundamental in advancing our projects.
Reaching this milestone is a significant achievement for Xeptiva, as it means our immunization meets a rigorous series of international standards that guarantee its safety and quality.
This is a fundamental step towards the clinical application of this promising therapeutic solution, bringing us closer to providing companion animals an effective and safe alternative to chronic pain that significantly improves their quality of life.
The industrial production of this first GMP-quality vaccine would not have been possible without significant investment in economic and human resources. Biotech development requires long-term commitment. For over 10 years, we have allocated funds for basic research, acquisition of new technologies, and ongoing training for our team at all levels.
It is crucial to highlight the collaboration with academic institutions such as the Institut Pasteur de Montevideo and industrial partners like ATGEN and Merck Argentina, as they have been fundamental in advancing our projects.
Reaching this milestone is a significant achievement for Xeptiva, as it means our immunization meets a rigorous series of international standards that guarantee its safety and quality.
This is a fundamental step towards the clinical application of this promising therapeutic solution, bringing us closer to providing companion animals an effective and safe alternative to chronic pain that significantly improves their quality of life.